NCT06048315
- Conditions
- Anlotinib, EGFR Sensitive Mutation, Lung Cancer, +9 more
- Locations
-
Not specified
Clinical trial condition
Explore clinical trials studying TKI Resistance. Study availability and eligibility vary by location and protocol.
NCT06048315
Not specified